Mergers: Commission adopts interim measures to prevent harm to competition following Illumina's early acquisition of GRAIL* The European Commission has adopted interim measures to restore and maintain the conditions of effective competition following Illumina's early acquisition of GRAIL, which is in breach of the standstill obligation under the EU Merger Regulation. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “By implementing their merger while the Commission's in-depth investigation into this transaction is still ongoing, Illumina and GRAIL have put at risk the effectiveness of our ex-ante merger control enforcement. This is why we are adopting today measures aiming to prevent harm to competition in the interim period until our final decision
Share on
|
|
The EU Commission adopts interim measures to prevent harm to competition following a merger between biological and pharmaceutical companies (Illumina / GRAIL)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
